Many Israeli concerns have been unsuccessful achieving the success that Teva has accomplished, because of the challenge in breaking into the innovation sector, the inability to raise proper funding for expansion, and the lack of experience in taking drugs through the regulatory process & to market.
By Reuters
As Israel’s biggest company Teva strives to get even bigger by swallowing up rival Mylan for more than $40 billion, further down the food chain a raft of upstart life science firms are struggling to climb onto the global ladder.

Photo: EPA
Now the government is starting to take notice, urged on by influential advocates, including Teva Pharmaceutical Industries’ own boss, who says the country’s economic future depends on replicating his company’s success. Continue Reading »






Prime real estate: Rothschild Boulevard in Tel Aviv






Israeli New Shekel Exchange Rate